New findings from an extended analysis of the CheckMate 274 trial offer fresh insight into post-surgical treatment for high-risk muscle-invasive bladder cancer. Curious how adjuvant nivolumab performs across patient subgroups? This quick read breaks down what you need to know.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


